Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

Completed · Phase 2

Conditions studied: Lymphoma, Follicular

In brief

Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

Key facts

Study ID

NCT00427856

Run by

Gemin X

People needed

7

Starts

2007-03-01

Expected to finish

2009-07-01

Last updated by the study team

2016-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathological confirmation of Follicular Lymphoma (FL)
• Must have advanced stage disease
• Must not have received any prior chemotherapy or immunotherapy for lymphoma, including steroids
• Must have adequate organ function
• Must have the ability to understand and willingness to sign a written informed consent form

You may not qualify if…

• No other agents or therapies administered with the intent to treat malignancy
• Uncontrolled, intercurrent illness
• Pregnant women and women who are breast feeding

Where it is running

• The Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.